Suppr超能文献

相似文献

1
The p21Waf1 pathway is involved in blocking leukemogenesis by the t(8;21) fusion protein AML1-ETO.
Blood. 2007 May 15;109(10):4392-8. doi: 10.1182/blood-2006-03-012575. Epub 2007 Feb 6.
2
A previously unidentified alternatively spliced isoform of t(8;21) transcript promotes leukemogenesis.
Nat Med. 2006 Aug;12(8):945-9. doi: 10.1038/nm1443. Epub 2006 Jul 30.
3
Transcriptional upregulation of p21/WAF/Cip1 in myeloid leukemic blasts expressing AML1-ETO.
Haematologica. 2008 Nov;93(11):1728-33. doi: 10.3324/haematol.13044. Epub 2008 Sep 11.
4
The myeloid master regulator transcription factor PU.1 is inactivated by AML1-ETO in t(8;21) myeloid leukemia.
Blood. 2003 Jan 1;101(1):270-7. doi: 10.1182/blood-2002-04-1288. Epub 2002 Aug 29.
8
AML1-ETO expression is directly involved in the development of acute myeloid leukemia in the presence of additional mutations.
Proc Natl Acad Sci U S A. 2001 Aug 28;98(18):10398-403. doi: 10.1073/pnas.171321298.
9
Dominant negative effects of the AML1/ETO fusion oncoprotein.
Cell Cycle. 2005 Jan;4(1):33-6. doi: 10.4161/cc.4.1.1399. Epub 2005 Jan 19.
10
An AML1-ETO/miR-29b-1 regulatory circuit modulates phenotypic properties of acute myeloid leukemia cells.
Oncotarget. 2017 Jun 20;8(25):39994-40005. doi: 10.18632/oncotarget.18127.

引用本文的文献

1
AML1/ETO and its function as a regulator of gene transcription via epigenetic mechanisms.
Oncogene. 2021 Sep;40(38):5665-5676. doi: 10.1038/s41388-021-01952-w. Epub 2021 Jul 30.
2
RNA-Binding Motif Protein 38 as a Potential Biomarker and Therapeutic Target in Cancer.
Onco Targets Ther. 2020 Dec 24;13:13225-13236. doi: 10.2147/OTT.S278755. eCollection 2020.
3
The RUNX1/RUNX1T1 network: translating insights into therapeutic options.
Exp Hematol. 2021 Feb;94:1-10. doi: 10.1016/j.exphem.2020.11.005. Epub 2020 Nov 17.
4
Caspase-3 controls AML1-ETO-driven leukemogenesis via autophagy modulation in a ULK1-dependent manner.
Blood. 2017 May 18;129(20):2782-2792. doi: 10.1182/blood-2016-10-745034. Epub 2017 Apr 5.
5
New insights into transcriptional and leukemogenic mechanisms of AML1-ETO and E2A fusion proteins.
Front Biol (Beijing). 2016 Aug;11(4):285-304. doi: 10.1007/s11515-016-1415-1. Epub 2016 Sep 3.
6
Supraphysiologic levels of the AML1-ETO isoform AE9a are essential for transformation.
Proc Natl Acad Sci U S A. 2016 Aug 9;113(32):9075-80. doi: 10.1073/pnas.1524225113. Epub 2016 Jul 25.
8
Integrative genetic analysis of mouse and human AML identifies cooperating disease alleles.
J Exp Med. 2016 Jan 11;213(1):25-34. doi: 10.1084/jem.20150524. Epub 2015 Dec 14.
9
Genome-wide co-occupancy of AML1-ETO and N-CoR defines the t(8;21) AML signature in leukemic cells.
BMC Genomics. 2015 Apr 17;16(1):309. doi: 10.1186/s12864-015-1445-0.

本文引用的文献

2
The tetramer structure of the Nervy homology two domain, NHR2, is critical for AML1/ETO's activity.
Cancer Cell. 2006 Apr;9(4):249-60. doi: 10.1016/j.ccr.2006.03.012.
3
AML1-ETO rapidly induces acute myeloblastic leukemia in cooperation with the Wilms tumor gene, WT1.
Blood. 2006 Apr 15;107(8):3303-12. doi: 10.1182/blood-2005-04-1656. Epub 2005 Dec 27.
5
Epigenetic inactivation of the CIP/KIP cell-cycle control pathway in acute leukemias.
Am J Hematol. 2005 Dec;80(4):282-7. doi: 10.1002/ajh.20503.
6
The hematopoietic transcription factor AML1 (RUNX1) is negatively regulated by the cell cycle protein cyclin D3.
Mol Cell Biol. 2005 Dec;25(23):10205-19. doi: 10.1128/MCB.25.23.10205-10219.2005.
7
Normal and transforming functions of RUNX1: a perspective.
J Cell Physiol. 2006 Jun;207(3):582-93. doi: 10.1002/jcp.20538.
9
The AML1-ETO fusion gene and the FLT3 length mutation collaborate in inducing acute leukemia in mice.
J Clin Invest. 2005 Aug;115(8):2159-68. doi: 10.1172/JCI24225. Epub 2005 Jul 14.
10
Absence of p21(CIP 1), p27(KIP 1) and p 57(KIP 2) methylation in MDS and AML.
Leuk Res. 2005 Nov;29(11):1357-60. doi: 10.1016/j.leukres.2005.04.012.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验